Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications

Table 1 Characteristics of the utilisation of risperidone after generic availability (month zero)

Consolidated atypical antipsychotics following generic risperidone
	Coefficient value (95% CI)	P -value
Initial intercept	22.70 (18.58 to 26.82)	<0.001
Change in intercept at month 0	−0.0774 (−1.080 to 0.925)	0.880
Initial slope	−0.144 (−0.158 to -0.130)	<0.001
Change in slope after month 0	−0.00548 (−0.0545 to 0.0436)	0.827

ISSN: 1741-7015